Carlos R Camara-Lemarroy
Carlos R Camara-Lemarroy
The successful landscape of relapsing remitting multiple sclerosis (RRMS) treatments has revolutionized our conceptualization of the disease. This led to a shifting interest towards finding ways of stopping neurodegeneration in progressive ...
Microstructural changes in juxtacortical white matter regions and their relationship with PASAT score in multiple sclerosis: A proof of concept using machine learning [0.03%]
利用机器学习探讨多发性硬化症皮质下白质微结构变化及其与PASAT评分的关系（概念验证）
Cristian Montalba,Pamela Franco,Raúl Caulier-Cisterna et al.
Cristian Montalba et al.
Background: Cognitive impairment is a common early feature of multiple sclerosis (MS). This decline may be linked to microstructural damage in juxtacortical U-fibers, which are highly vulnerable to early demyelination and...
The value of neutrophil to high-density lipoprotein ratio in anti-NMDAR encephalitis [0.03%]
中性粒细胞与高密度脂蛋白比率在抗N-甲基-D天冬氨酸受体脑炎中的价值分析
Sai Wang,Lanjun Li,Haiman Hou et al.
Sai Wang et al.
Purpose: This study aimed to investigate the association of the neutrophil to high-density lipoprotein ratio (NHR) with disease severity and short-term prognosis at discharge in anti-N-methyl-D-aspartic acid receptor (NMD...
Predictors of early response to cladribine in mexican patients with multiple sclerosis: A real world multicenter retrospective cohort study [0.03%]
墨西哥多发性硬化患者克拉利din早期反应的预测因素：一项真实世界多中心回顾性队列研究
C J Moreno-Bernardino,I Treviño-Frenk,J F Ortiz-Maldonado et al.
C J Moreno-Bernardino et al.
Background: Multiple sclerosis (MS) is a leading cause of neurological disability in young adults. In Mexico, its impact is considerable, driven by functional impairments and cognitive decline. Cladribine, an oral immune ...
Real-world impact of national policy on high-efficacy therapy use in multiple sclerosis: A Brazilian big data analysis [0.03%]
巴西多发性硬化高疗效治疗的国家政策的真实世界影响：大数据分析
Alexandre Coelho Marques,Marina Martins Siqueira,Gabriely Rangel Pereira et al.
Alexandre Coelho Marques et al.
Background: In 2021, Brazil updated its Clinical Protocol and Therapeutic Guidelines (PCDT) for multiple sclerosis (MS), expanding first-line eligibility for natalizumab (NTZ) in patients with highly active disease and in...
Diagnostic delay in patients with myelin oligodendrocyte antibody-associated disease presenting with elevated intracranial pressure [0.03%]
与颅内压升高相关的髓鞘少突胶质细胞抗体相关疾病诊断延迟患者的临床特征分析
Taylor M Lakusta-Wong,Kenrick E Wysong,Andrew J Solomon
Taylor M Lakusta-Wong
Background: Elevated intracranial pressure (ICP) is a recently recognized complication of myelin oligodendrocyte antibody associated disease (MOGAD). Obje...
Economic and social burden of multiple sclerosis in Morocco: a tertiary care center study [0.03%]
摩洛哥多发性硬化症的经济和社会负担：一家三级护理中心的研究
Hicham El Otmani,Kaoutar Simma,Hajar El Omari et al.
Hicham El Otmani et al.
Background: Multiple sclerosis (MS) imposes substantial clinical, economic, and social consequences, particularly in young adults during their most productive years. While the societal cost of MS has been extensively stud...
Metabolic dysfunction in multiple sclerosis: Elevated lactate and impaired post-exercise creatine response in the anterior cingulate cortex [0.03%]
多发性硬化症中的代谢功能障碍：前扣带回皮层乳酸升高和运动后肌酸反应受损
Gemma Brownbill,Jeanne Dekerle,Mara Cercignani et al.
Gemma Brownbill et al.
Background: Multiple Sclerosis (MS) is characterised by altered brain metabolism and increased chronic perceived fatigue. However, the relationship between brain metabolites, fatigue, and physical task effects in MS remai...
Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis [0.03%]
血清神经丝轻链用于指导多发性硬化症诊疗的准确性如何？系统评价和 Meta 分析的诊断性能及最佳临界值探讨
João Lucas Silva Santana,Rafael Martins Themoteo,Gabriela Abrahão Allioni et al.
João Lucas Silva Santana et al.
Background: Serum neurofilament light chain (sNfL) has emerged as a minimally invasive biomarker reflecting neuroaxonal injury in multiple sclerosis (MS), with potential utility for detecting inflammatory disease activity...
Fingolimod for pediatric multiple sclerosis: The Ped-MS group systematic review and meta-analysis [0.03%]
儿童多发性硬化症的芬戈莫德治疗：Ped-MS小组的系统评价和荟萃分析
Hasan Kaveyee,Masoud Etemadifar,Amir Parsa Abhari et al.
Hasan Kaveyee et al.
Background: Selecting the optimum disease-modifying therapy (DMT) for pediatric multiple sclerosis (Ped-MS) poses a significant challenge and requires special attention. If untreated or treated inappropriately, PED-MS can...